AMJ Podcast | Episode 1: Harnessing Imaging Biomarkers in Asthma: Lessons from VESTIGE

This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.

Join us for this two-episode mini-series featuring lead study authors, Mario Castro and Njira Lugogo, as they discuss key findings from the VESTIGE trial and their implications on asthma care.

 Uncover:

• The importance of patient phenotyping: How can biomarkers and imaging improve asthma management?
• Mucus plugging and airflow obstruction: What does the latest research reveal?
• Biologics and airway remodeling: What did the VESTIGE trial reveal about biologics and airway remodeling?
• The role of imaging in clinical practice: How can CT scans provide new insights into asthma care?

Part 1: Emerging Technologies in Asthma Management

Spotify | Apple | Amazon Music | Download MP3 (14 mins)

Part 2: Key Findings and Clinical Application

Spotify | Apple | Amazon Music | Download MP3 (20 mins)

Disclaimers:

• This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
• The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program
• The content contained in this program was jointly developed by AMJ, the speakers, and Sanofi and Regeneron, and is not eligible for continuing medical education (CME) credits
• See full US Prescribing Information for dupilumab
• MAT-US-2412937 v2.0 – Pro1 Expiration Date: 04/21/2026

Speaker disclosures:

• MC reports research support from the American Lung Association, AstraZeneca, Gala Therapeutics, Genentech, GSK, NIH, Novartis, PCORI, Pulmatrix, sanofi-aventis, Shionogi, and Theravance Biopharma, consultancy fees from Allakos, Amgen, Arrowhead Pharmaceuticals, Blueprint Medicines, Connect BioPharma, Genentech, GSK, Merck, Novartis, OM Pharma, Pfizer, Pioneering Medicines, sanofi-aventis, Teva, Third Rock Ventures, and Verona Pharmaceuticals, speaker fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals Inc., and Sanofi, and royalties from Aer Therapeutics.
• NLL reports research support paid to institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, consultancy fees from and participation on advisory boards with Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Teva, travel support from AstraZeneca, and honoraria for non-speaker bureau presentations from AstraZeneca and GSK.

References:

1. Castro M et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2025;13:208-20. doi: 10.1016/S2213-2600(24)00362-X.